Michael Okunewitch
Stock Analyst at Maxim Group
(0.36)
# 3,151
Out of 4,415 analysts
14
Total ratings
16.67%
Success rate
-17.27%
Average return
Main Sectors:
Top Industries:
11 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEXX Lexaria Bioscience | Maintains: Buy | $3 → $12 | $3.00 | +300.00% | 2 | Mar 5, 2024 | |
| ACRV Acrivon Therapeutics | Initiates: Buy | $24 | $8.46 | +183.69% | 1 | Oct 5, 2023 | |
| ANEB Anebulo Pharmaceuticals | Initiates: Buy | $6 | $3.16 | +89.87% | 1 | Sep 21, 2023 | |
| KPRX Kiora Pharmaceuticals | Maintains: Buy | $12 → $2 | $0.54 | +268.60% | 3 | Aug 9, 2023 | |
| ALZN Alzamend Neuro | Initiates: Buy | $23 | $0.73 | +2,992.78% | 1 | Apr 12, 2023 | |
| MDWD MediWound | Initiates: Buy | $25 | $18.84 | +32.70% | 1 | Dec 22, 2022 | |
| BRTX BioRestorative Therapies | Initiates: Buy | $6 | $1.46 | +310.96% | 1 | Sep 28, 2022 | |
| HCWB HCW Biologics | Initiates: Buy | $4 | $1.32 | +203.03% | 1 | Mar 24, 2022 | |
| LGVN Longeveron | Initiates: Buy | $140 | $1.81 | +7,634.81% | 1 | Mar 24, 2022 | |
| ATAI Atai Life Sciences | Initiates: Buy | n/a | $2.13 | - | 1 | Nov 30, 2021 | |
| CTXR Citius Pharmaceuticals | Initiates: Buy | n/a | $0.71 | - | 1 | Nov 30, 2021 |
Lexaria Bioscience
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $3.00
Upside: +300.00%
Acrivon Therapeutics
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $8.46
Upside: +183.69%
Anebulo Pharmaceuticals
Sep 21, 2023
Initiates: Buy
Price Target: $6
Current: $3.16
Upside: +89.87%
Kiora Pharmaceuticals
Aug 9, 2023
Maintains: Buy
Price Target: $12 → $2
Current: $0.54
Upside: +268.60%
Alzamend Neuro
Apr 12, 2023
Initiates: Buy
Price Target: $23
Current: $0.73
Upside: +2,992.78%
MediWound
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $18.84
Upside: +32.70%
BioRestorative Therapies
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.46
Upside: +310.96%
HCW Biologics
Mar 24, 2022
Initiates: Buy
Price Target: $4
Current: $1.32
Upside: +203.03%
Longeveron
Mar 24, 2022
Initiates: Buy
Price Target: $140
Current: $1.81
Upside: +7,634.81%
Atai Life Sciences
Nov 30, 2021
Initiates: Buy
Price Target: n/a
Current: $2.13
Upside: -
Citius Pharmaceuticals
Nov 30, 2021
Initiates: Buy
Price Target: n/a
Current: $0.71
Upside: -